Current Diabetes Reports最新文献_第3页

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments. 行为干预能促进儿童1型糖尿病的健康公平吗？前景治疗的叙述性回顾。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-05-30 DOI: 10.1007/s11892-026-01629-2

Paul T Enlow, Jaquelin Flores Garcia, Julia Price, Kristen A Torres, David V Wagner

{"title":"Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.","authors":"Paul T Enlow, Jaquelin Flores Garcia, Julia Price, Kristen A Torres, David V Wagner","doi":"10.1007/s11892-026-01629-2","DOIUrl":"10.1007/s11892-026-01629-2","url":null,"abstract":"Purpose of review: Synthesize data on whether existing behavioral interventions can improve health equity among youth with type 1 diabetes.Recent findings: While existing behavioral interventions demonstrated efficacy in improving health and/or psychosocial outcomes, evidence that these same interventions may improve health equity were lacking. Most interventions were evaluated using predominantly White and affluent samples and some studies did not report on racial, ethnic, or sociodemographic characteristics of their sample. Only a few interventions have been adapted for youth from minoritized backgrounds. Recent multisystemic and technology/mHealth interventions recruited samples that were sociodemographically representative of youth experiencing disparities, suggesting that these interventions could improve health and/or psychosocial outcomes for these sociodemographic groups. However, no studies conducted subgroup analyses to examine whether the effect of the intervention might vary as a function of sociodemographic characteristics. The prevalence and persistence of disparities in psychosocial and glycemic outcomes among youth with T1D underscore the urgent need for effective, evidence-based behavioral interventions for populations in most need of this care. There is a critical need for research that prioritizes recruitment of samples that represent youth most impacted by health disparities. Additionally, existing interventions can be adapted for youth from minoritized backgrounds. Future research would benefit from leveraging existing intervention development/adaptation frameworks and engaging community partners through the research process.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Implementation Strategies to Address Cardiometabolic Disparities in Black Men: Lessons from Existing Research and Future Directions. 更正：解决黑人男性心脏代谢差异的实施策略：来自现有研究和未来方向的教训。

IF 6.4 2区医学

Current Diabetes Reports Pub Date : 2026-05-22 DOI: 10.1007/s11892-026-01630-9

Jaclynn Hawkins

引用次数: 0

Type 2 Diabetes and the Lung - Cause and Consequence. 2型糖尿病与肺部——原因和后果。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-05-07 DOI: 10.1007/s11892-026-01625-6

Dinah Foer, Tianshi David Wu, Juan C Celedón, M Furkan Burak, Vanita R Aroda

{"title":"Type 2 Diabetes and the Lung - Cause and Consequence.","authors":"Dinah Foer, Tianshi David Wu, Juan C Celedón, M Furkan Burak, Vanita R Aroda","doi":"10.1007/s11892-026-01625-6","DOIUrl":"10.1007/s11892-026-01625-6","url":null,"abstract":"Purpose of review: The purpose of this review is to synthesize literature investigating the relationship between type 2 diabetes (T2D) and obstructive airway diseases and to identify implications for clinical care.Recent findings: Type 2 diabetes is a common and challenging comorbidity in patients with asthma and chronic obstructive pulmonary disease (COPD). Basic, translational and clinical studies support a bidirectional association between T2D and the lung. In animal models and human studies, insulin resistance and hyperglycemia are associated with pulmonary inflammation, respiratory exacerbation risk and disease severity. Corticosteroids are a mainstay for respiratory disease control and exacerbation treatment but promote ongoing metabolic dysregulation. Randomized, placebo-controlled trials of glucose-lowering medications for asthma are actively ongoing. Additional studies addressing clinical pathways to co-manage respiratory and metabolic risk are needed. Patients with comorbid T2D and asthma or COPD are at risk for worse outcomes. There are opportunities to improve cross-disciplinary care, potentially reducing risk and multimorbidity associated with both conditions.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes. 2型糖尿病肥胖的药物治疗

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-13 DOI: 10.1007/s11892-026-01626-5

Caterina Conte, Anastassia Amaro

{"title":"Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.","authors":"Caterina Conte, Anastassia Amaro","doi":"10.1007/s11892-026-01626-5","DOIUrl":"10.1007/s11892-026-01626-5","url":null,"abstract":"Purpose of review: To examine the role of pharmacologic obesity treatment in people with type 2 diabetes (T2D), with a focus on efficacy, safety, and clinical positioning in the context of T2D-specific metabolic and therapeutic challenges.Recent findings: Contemporary incretin receptor agonists enable clinically meaningful weight loss in people with T2D while improving glycemic control and cardio-renal, hepatic, and functional outcomes, including improvements in physical performance and symptoms in heart failure with preserved ejection fraction (HFpEF). However, weight loss is consistently attenuated compared with obesity without diabetes, reflecting reduced metabolic flexibility (impaired ability to appropriately adjust fuel utilization), background therapies, and social determinants of health rather than treatment failure. Obesity pharmacotherapy should be considered a disease-modifying component of T2D care. Treatment success should be defined by improvements in adiposity-related complications, organ protection, and patient-centered outcomes, not by fixed weight-loss thresholds. A complication-focused, individualized approach is essential to optimize long-term benefit in T2D.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes. 肠-脂肪组织-肝轴的失调：代谢功能障碍相关的脂肪变性肝病与2型糖尿病之间关系的可能机制

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-11 DOI: 10.1007/s11892-026-01623-8

Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici

{"title":"Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.","authors":"Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici","doi":"10.1007/s11892-026-01623-8","DOIUrl":"10.1007/s11892-026-01623-8","url":null,"abstract":"Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a hepatic manifestation of metabolic syndrome, frequently occurring alongside type 2 diabetes (T2D), and it can present in varied phenotypes. This review provides a critical analysis of gut-adipose tissue-liver axis (GALA) dysregulation in MASLD pathogenesis, contextualizing the discussion within both established and emerging paradigms. The review elucidates how GALA dysregulation shapes the interplay between MASLD and T2D, emphasizing inter-organ crosstalk among the gut, liver, and adipose tissue, and highlighting the role of microbial metabolites, notably bile acids. The review further summarizes recent advances in stratifying MASLD into distinct clusters, examining intricate associations with cardiometabolic comorbidities, and critically evaluates novel therapeutic approaches targeting GALA modulation.Recent findings: MASLD can show heterogeneous phenotypes. It significantly increases the risk of developing new-onset T2D, and both conditions often coexist due to their shared pathophysiological basis in insulin resistance. The gut microbiota influences immune function and modulates host metabolism by regulating glucose tolerance and insulin sensitivity through a specific crosstalk between the gut, liver, and adipose tissue. The dysregulation of the GALA may be a mechanism underlying the interplay between MASLD and T2D, influencing IR and metabolic syndrome. A thorough investigation of GALA's role in the physiopathogenesis of MASLD and T2D highlights its potential to distinguish specific MASLD clusters and to identify personalized therapeutic strategies.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes. 更正：胰高血糖素样肽-1和双重肠促胰岛素激动剂治疗伴有外周动脉疾病的2型糖尿病：血管、心血管、代谢和死亡率结局的系统回顾和荟萃分析。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-10 DOI: 10.1007/s11892-026-01622-9

Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi

引用次数: 0

Lipolysis in Health and Disease: Pathways, Regulation, and Metabolic Consequences. 健康和疾病中的脂肪分解：途径、调节和代谢后果。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-10 DOI: 10.1007/s11892-026-01624-7

Courtney L Bordelon, Jacqueline M Stephens

{"title":"Lipolysis in Health and Disease: Pathways, Regulation, and Metabolic Consequences.","authors":"Courtney L Bordelon, Jacqueline M Stephens","doi":"10.1007/s11892-026-01624-7","DOIUrl":"10.1007/s11892-026-01624-7","url":null,"abstract":"PURPOSE OF REVIEW: Lipolysis regulates lipid distribution, energy availability, and metabolic homeostasis in organisms that store triacylglycerols. In multicellular organisms, adipose tissue evolved as a specialized organ that centralizes lipid storage and release, buffers nutrient fluctuations, and protects non-adipose tissues from lipid overload. Dysregulated adipocyte lipolysis occurs across diverse metabolic conditions, including obesity, diabetes, lipodystrophy, and inflammatory states. This review synthesizes evidence that defective suppression of basal lipolysis and impaired responsiveness to physiological stimuli disrupt lipid partitioning, promote insulin resistance, and drive ectopic lipid accumulation. RECENT FINDINGS: Research shows that metabolic dysfunction arises in both obese and non-obese settings and correlates more closely with impaired control of fatty acid flux than with adiposity itself. Higher expression of lipolytic receptors, including those targeted by weight-loss medications, together with genes that regulate lipolysis through insulin signaling, is associated with greater weight loss and improved systemic metabolic health. In this review, we highlight canonical and noncanonical mechanisms governing lipolytic regulation and contrast pathological lipolysis with the tightly controlled lipolysis observed during weight loss. Together, these findings reframe lipolysis as a central determinant of metabolic health and a therapeutic target when precisely regulated. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of the Fear of Hypoglycemia Literature in Children and Adolescents with Type 1 Diabetes and their Caregivers. 儿童和青少年1型糖尿病患者及其照护者对低血糖的恐惧文献综述

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-23 DOI: 10.1007/s11892-026-01620-x

Kimberly A Driscoll, Paige J Trojanowski, Emily R Shaffer, Hannah Manis, Alicia Pardon, Cheyenne M Reynolds, Sara E Wetter-Wren, Holly K O'Donnell, Susana R Patton

引用次数: 0

Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. 2型糖尿病患者代谢功能障碍相关脂肪变性肝病的药物治疗

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-14 DOI: 10.1007/s11892-026-01621-w

Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos

{"title":"Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.","authors":"Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos","doi":"10.1007/s11892-026-01621-w","DOIUrl":"10.1007/s11892-026-01621-w","url":null,"abstract":"PURPOSE OF REVIEW: Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D). This review summarizes current evidence on the pharmacologic treatment of MASLD, with emphasis on agents currently approved for the management of T2D. RECENT FINDINGS: Among glucose-lowering therapies, GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors demonstrate meaningful benefits in steatohepatitis. Semaglutide provides the most robust evidence for fibrosis benefit, while data suggest potential antifibrotic effects of tirzepatide and dapagliflozin. Resmetirom and semaglutide are the only agents specifically approved for MASLD. An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit. Additional therapies, including pan-PPAR agonists, and FGF21 analogues are advancing through phase 3 development. The therapeutic landscape is rapidly evolving toward integrated metabolic, hepatic, and cardiovascular risk reduction in T2D and MASLD. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD. 胰高血糖素样肽-1和双重肠促胰岛素激动剂治疗伴有外周动脉疾病的2型糖尿病：血管、心血管、代谢和死亡率结局的系统回顾和荟萃分析：肠促胰岛素治疗T2DM和PAD

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-10 DOI: 10.1007/s11892-026-01619-4

Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi

{"title":"Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.","authors":"Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi","doi":"10.1007/s11892-026-01619-4","DOIUrl":"10.1007/s11892-026-01619-4","url":null,"abstract":"PURPOSE OF REVIEW: Peripheral artery disease (PAD) is a serious complication in type 2 diabetes, increasing vascular morbidity and mortality. While glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists show cardiovascular benefits in diabetes, their effects on PAD-related outcomes are unclear. This meta-analysis assessed the impact of these therapies on vascular outcomes in type 2 diabetes with PAD. RECENT FINDINGS: A systematic review and meta-analysis were conducted per PRISMA guidelines (PROSPERO CRD420251083622). PubMed, Embase, and Cochrane Central were searched. A random-effects model pooled data. Primary outcomes were major adverse limb events, peripheral revascularization, and amputation. Secondary outcomes included major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction, stroke, HbA1c, and weight changes. Six studies (four RCTs, two propensity score-matched cohorts) with 25,866 patients were included. Incretin-based therapies significantly reduced all-cause mortality (RR 0.52 [0.28–0.95], p = 0.032) and HbA1c (MD − 0.73% [–1.32 to − 0.15], p = 0.013) compared to placebo or standard care. No significant differences were found for major adverse limb events, revascularization, amputation, MACE, myocardial infarction, or stroke. Heterogeneity and low evidence certainty were noted. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0